Clinical Trial Update: Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy

View source ↗

Summary

A completed clinical trial evaluating nivolumab in metastatic renal cell carcinoma, examining regulatory T cell function, T-cell access, and natural killer cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: RCC, Metastatic Renal Cell Carcinoma | Status: COMPLETED